Amicus Therapeutics (FOLD) said Monday that preliminary results from an ongoing Phase 2 open-label drug-drug interaction study to evaluate AT2220 was positive.
The study was conducted to evaluate the safety and pharmacokinetic effects of pharmacological chaperone AT2220 co-administered with enzyme replacement therapy for Pompe disease.
John Crowley, chairman and chief executive officer of the company, said, "It is a great step forward in the development of this Amicus platform technology in Pompe disease and we look forward to additional important data from the remaining two cohorts in this clinical study."
For comments and feedback: editorial@rttnews.com